首页> 中文期刊> 《中华医学杂志(英文版)》 >Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia

Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia

         

摘要

Background:Serum antinuclear antibodies (ANAs) are positive in some patients with chronic lymphocytic leukemia (CLL),but the prognostic value of ANAs remains unknown.The aim of this study was to evaluate the role of ANAs as a prognostic factor in CLL.Methods:This study retrospectively analyzed clinical data from 216 newly diagnosed CLL subjects with ANAs test from 2007 to 2017.Multivariate Cox regression analyses were used to screen the independent prognostic factors related to time to first treatment (TTFT),progression free survival (PFS) and overall survival (OS).Receiver operator characteristic curves and area under the curve (AUC) were utilized to assess the predictive accuracy of ANAs together with other independent factors for OS.Results:The incidence of ANAs abnormality at diagnosis was 13.9%.ANAs positivity and TP53 disruption were independent prognostic indicators for OS.The AUC of positive ANAs together with TP53 disruption was 0.766 (95% confidence interval [CI]:0.697-0.826),which was significantly larger than that of either TP53 disruption (AUC:0.706,95% CI:0.634-0.772,P=0.034) or positive ANAs (AUC:0.595,95% CI:0.520-0.668,P < 0.001) in OS prediction.Besides,serum positive ANAs as one additional parameter to CLL-international prognostic index (IPI) obtained superior AUCs in predicting CLL OS than CLL-IPI alone.Contusion:This study identified ANAs as an independent prognostic factor for CLL,and further investigations are needed to validate this finding.

著录项

  • 来源
    《中华医学杂志(英文版)》 |2019年第5期|525-533|共9页
  • 作者单位

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China;

    Collaborative Innovation Center for Cancer Personalized Medicine, Key Laboratory of Hematology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;

  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号